Compare TJX & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TJX | REGN |
|---|---|---|
| Founded | 1962 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.6B | 84.3B |
| IPO Year | 1994 | 1995 |
| Metric | TJX | REGN |
|---|---|---|
| Price | $140.39 | $919.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 28 |
| Target Price | $165.55 | ★ $991.00 |
| AVG Volume (30 Days) | ★ 5.3M | 869.8K |
| Earning Date | 11-18-2026 | 10-30-2026 |
| Dividend Yield | ★ 1.38% | 0.41% |
| EPS Growth | ★ 14.32 | 8.19 |
| EPS | 2.55 | ★ 37.37 |
| Revenue | ★ $29,078,407,000.00 | $5,872,227,000.00 |
| Revenue This Year | $6.09 | $31.18 |
| Revenue Next Year | $6.20 | $7.19 |
| P/E Ratio | $54.69 | ★ $24.71 |
| Revenue Growth | 6.04 | ★ 20.82 |
| 52 Week Low | $122.81 | $591.52 |
| 52 Week High | $170.00 | $991.73 |
| Indicator | TJX | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 57.41 |
| Support Level | $122.81 | $735.26 |
| Resistance Level | $161.43 | $986.64 |
| Average True Range (ATR) | 4.38 | 32.57 |
| MACD | 0.09 | -4.43 |
| Stochastic Oscillator | 63.03 | 32.58 |
Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.